Provides readers with first-hand advice for the development of novel antimalarial drugs

This book provides a systematic overview of antimalarial drug development and presents a wealth of data and insight from drug developers across three continents, including many from countries where the disease is endemic. Throughout, the contributions have been written with the drug developer in mind, highlighting challenges but also opportunities for the successful development of effective antimalarial drugs. Case studies and method-oriented chapters provide an abundance of practical first-hand advice on how to successfully develop an antimalarial drug.

Key topics covered in the book include:

• The performance of current drugs and therapies, the influence of formulation and targeted delivery, and strategies to overcome drug resistance.
• Technologies and approaches for development of novel drugs, such as assays, computer-aided drug design, known and potential drug targets, and natural sources for novel antimalarial compounds
• Vaccination as an alternative to drug therapy

For chemists and other professionals working in industries related to medicine and pharmaceuticals, this book provides a completely comprehensive overview of the current state of novel antimalarial drugs and how they can be developed in an efficient and cost-effective manner.

Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. He also holds a position as business development director with T&T Pharma Care in Thane (India). The primary focus of his work is in antimalarial therapy.